Clinical Experience with Intravenous Estramustine Phosphate, Paclitaxel, and Carboplatin in Patients with Castrate, Metastatic Prostate Adenocarcinoma Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin
  • Estramustine
  • Paclitaxel
  • Prostatic Neoplasms

abstract

  • Intravenous EMP was administered safely with paclitaxel and carboplatin and produced clinical outcomes similar to the outcomes achieved with the TEC regimen. Substitution of i.v. EMP for the oral formulation was found to result in a lower incidence of severe nausea but increased hepatic toxicity.

publication date

  • November 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.11754

PubMed ID

  • 14584065

Additional Document Info

start page

  • 1842

end page

  • 8

volume

  • 98

number

  • 9